News on Xyzal from BioPortfolio.com http://www.BioPortfolio.com Consolidated Xyzal news from BioPortfolio.com Wed, 10 Feb 2010 00:25:03 GMT en Sanofi-Aventis acquires marketing rights to Xyzalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007417&HITNO=0&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007417&THISHREF=http://c.moreover.com/click/here.pl%3fz2521120979%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007417&HITNO=0&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007417&THISHREF=http://c.moreover.com/click/here.pl%3fz2521120979%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comThe Tan Sheet: UCB accelerates transition to become patient-centric global biopharmaceutical leaderhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992000&HITNO=1&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992000&THISHREF=http://c.moreover.com/click/here.pl%3fz2513951235%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992000&HITNO=1&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992000&THISHREF=http://c.moreover.com/click/here.pl%3fz2513951235%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Europe: UCB (BE) - UCB Accelerates Transition to Become Patient-Centric Global Biopharmaceutical Leader With Decisionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991803&HITNO=2&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991803&THISHREF=http://c.moreover.com/click/here.pl%3fz2513879075%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991803&HITNO=2&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991803&THISHREF=http://c.moreover.com/click/here.pl%3fz2513879075%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit thehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991244&HITNO=3&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991244&THISHREF=http://c.moreover.com/click/here.pl%3fz2513623730%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991244&HITNO=3&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991244&THISHREF=http://c.moreover.com/click/here.pl%3fz2513623730%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: UCB accelerates transition to become patient-centric globalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991109&HITNO=4&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991109&THISHREF=http://c.moreover.com/click/here.pl%3fz2513562659%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991109&HITNO=4&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991109&THISHREF=http://c.moreover.com/click/here.pl%3fz2513562659%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Europe: UCB Accelerates Transition To Become Patient-centric Global Biopharmaceutical Leader With Decision To Exit Thehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991020&HITNO=5&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991020&THISHREF=http://c.moreover.com/click/here.pl%3fz2513534724%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991020&HITNO=5&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991020&THISHREF=http://c.moreover.com/click/here.pl%3fz2513534724%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Belgium's UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Tevahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992626&HITNO=6&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992626&THISHREF=http://c.moreover.com/click/here.pl%3fz2514271513%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992626&HITNO=6&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992626&THISHREF=http://c.moreover.com/click/here.pl%3fz2514271513%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Letter: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit thehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3985354&HITNO=7&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3985354&THISHREF=http://c.moreover.com/click/here.pl%3fz2508586028%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3985354&HITNO=7&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3985354&THISHREF=http://c.moreover.com/click/here.pl%3fz2508586028%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984605&HITNO=8&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984605&THISHREF=http://c.moreover.com/click/here.pl%3fz2508232906%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984605&HITNO=8&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984605&THISHREF=http://c.moreover.com/click/here.pl%3fz2508232906%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit thehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984589&HITNO=9&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984589&THISHREF=http://c.moreover.com/click/here.pl%3fz2508227642%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984589&HITNO=9&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984589&THISHREF=http://c.moreover.com/click/here.pl%3fz2508227642%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984581&HITNO=10&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984581&THISHREF=http://c.moreover.com/click/here.pl%3fz2508223844%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984581&HITNO=10&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984581&THISHREF=http://c.moreover.com/click/here.pl%3fz2508223844%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984579&HITNO=11&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984579&THISHREF=http://c.moreover.com/click/here.pl%3fz2508222726%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984579&HITNO=11&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984579&THISHREF=http://c.moreover.com/click/here.pl%3fz2508222726%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984578&HITNO=12&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984578&THISHREF=http://c.moreover.com/click/here.pl%3fz2508222567%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984578&HITNO=12&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984578&THISHREF=http://c.moreover.com/click/here.pl%3fz2508222567%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care markhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984576&HITNO=13&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984576&THISHREF=http://c.moreover.com/click/here.pl%3fz2508217958%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984576&HITNO=13&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984576&THISHREF=http://c.moreover.com/click/here.pl%3fz2508217958%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEuroInvestor.co.uk: UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market ..http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984439&HITNO=14&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984439&THISHREF=http://c.moreover.com/click/here.pl%3fz2508166296%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3984439&HITNO=14&MSIZE=17&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xyzal&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3984439&THISHREF=http://c.moreover.com/click/here.pl%3fz2508166296%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: